Insights in Neurosurgery

Sequencing of the saliva of normal person and AD patients

4^th International Conference on BRAIN DISORDERS AND DEMENTIA CARE
August 14-16, 2017 | Toronto, Canada

Ki-Bong Song and Yo-Han Choi

ETRI, Korea

Posters & Accepted Abstracts: Neurosurg

DOI: 10.21767/2471-9633-C1-006

Abstract

Recently, we show that salivary �²-amyloid protein (A�²) can be a potential biomarker to early diagnose Alzheimerâ��s Disease (AD). At results, the quantity of A�²40 and A�²42 in the saliva of normal young man (nYM) group, normal elderly (nE) group and AD patients was measured in the range from very low concentration (~ pg/ml) to high concentration (~ng/ ml). To find out another bio-marker in the saliva, using Malditof, we analyzed the size of the salivary protein below less than 20 kDa. As a result, we found that there was a specific protein which can distinguish the Np from the AD patients and the size of that was about 15 kDa. In this study, we will briefly introduce that the sequencing results for the salivary protein which can distinguish between Np from the severe AD patients. Therefore, we expect these results to further increase the accuracy of the diagnosis of AD when the A�² level diagnosis was adapted simultaneously.

Biography

Ki-Bong Song has received his PhD degree in Physics, from the Department of Physics of Sogang University, Korea. After working as a Post-doc in KIST (Korea Institute of Science and Technology), he is now a Principal Researcher in ETRI (Electronics and Telecommunications Research Institute), Korea. His main research includes diagnosing technique in AD and development of wearable technology.